Millions of patients suffer from Parkinson’s and Alzheimer’s, yet current therapeutic development is failing. The core problem is that the medical community is aggressively directing resources toward disease treatments without a fundamental understanding of the specific molecules and chemical pathways causing these conditions. We cannot develop better drugs if we do not understand the underlying neurochemistry. Currently, we lack the technological capability to measure real-time, neuron-to-neuron chemical communication. Without the ability to map these complex neurochemical fluctuations, our disease models are incomplete, and drug development remains a guessing game.
The challenge we address is this pressing technological gap. We must shift our focus back to basic science to capture fundamental molecular insights into brain pathophysiology. Only by decoding the exact chemical drivers of these diseases can we successfully guide the development of targeted, life-saving therapeutics.
